Company Information

  

Address: BAHNHOFSTRASSE 21  
City: 6300 ZUG 
State:  
Zip Code: 00000 
Telephone: 41 (0)61 201 13 50 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. We have two lead clinical-stage product candidates, (i) Keyzilen┬« (AM-101), which is being developed for the treatment of acute inner ear tinnitus and (ii) AM-111, being developed for the treatment of acute inner ear hearing loss and has been granted orphan drug status by the FDA and the EMA and has been granted fast track designation by the FDA. AM-125 is being developed for the treatment of vestibular disorders. In addition, we are pursuing early stage projects for the treatment of tinnitus. Our product candidates Keyzilen┬« and AM-111 are injected under local anesthesia into the middle ear by a technique called intratympanic injection. Once injected into the middle ear, the active substance, which is formulated in a biocompatible gel, diffuses into the inner ear.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
12/2017-5.60NAN/E
12/2016-89.00NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.18Total Liab/Total Assets1.12
Net Inc/Total Assets-1.37Total Liab/Inv Cap6.99
Net Inc/Inv Cap-8.54Total Liab/Comm Equity0.15
Pretax Inc/Net SalesNAInterest Coverage Ratio-13.89
Net Inc/Net SalesNACurr Debt/Equity-2.10
Cash Flow/Net SalesNALTD/Equity-3.43
SG&A/NetSalesNATotal Debt/Equity-5.53
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio1.52
Inventory TurnoverNACurrent Ratio1.52
Inventory Day SalesNANet Rec/Curr Assets0.02
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 5.29 5.36 4.34 4.52
Operating Income -25.00 -29.74 -30.85 -22.34
Interest Exp 1.68 0.82 0.01 0.06
Pretax Income -25.07 -30.30 -29.68 -18.30
Other Income 1.62 0.25 1.18 4.09
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -25.05 -30.17 -29.68 -18.30

Balance Sheet (Millions)

Assets 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Cash & Short Term Investments 15.37 31.92 50.19 57.30
Receivables - Total 0.25 0.29 0.65 0.55
Inventories - Total NA NA NA NA
Total Current Assets 16.28 33.15 51.02 58.11
Net Property, Plant & Equipment 0.26 0.36 0.22 0.24
Total Assets 18.29 35.08 52.76 59.87
Liabilities        
Accounts Payable 6.04 6.64 6.16 4.47
Debt in Current Liabilities 4.66 2.18 0.00 NA
Total Current Liabilities 10.70 8.81 6.16 4.47
Long-Term Debt 7.62 10.10 0.00 NA
Total Liabilities 20.51 21.17 8.06 6.25
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 19.86 13.51 13.71 11.68
Retained Earnings -139.69 -110.54 -81.50 -52.46
Treasury Stock NA NA NA NA
Total Stockholders' Equity -2.22 13.92 44.70 53.62
Total Liabilities and Stockholders' Equity 18.29 35.08 52.76 59.87

Cash Flow Summary (Millions)

Categories 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Cash Provided by Operating Activities -24.91 -28.98 -28.70 -19.44
Net Cash Provided by Investing Activities -0.10 -0.17 -0.04 -1.19
Net Cash Provided by Financing Activities 8.44 11.25 20.90 49.93

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-16.87--
12/20140.00-18.30--
12/20150.00-29.68--
12/20160.00-30.17-89.00
12/20170.00-25.05-5.60
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/18182,36838.72




Report Date : 6/18/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.